Abbott Laboratories

Abbott Laboratories

ABT·NYSE

$87.02

-0.82%
HealthcareMedical - Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

At a Glance

Live Snapshot
Market Cap$151.57B
EPS3.7400
P/E Ratio23.27
Earnings Date07/16/2026

abt

Revenue

Last Annual Value

44.33B

3-Year CAGR

1%

5-Year CAGR

5%

10-Year CAGR

8%

Abbott Laboratories

Abbott Laboratories Competitors Analysis of Revenue

ABT · NYSE
CompanyRevenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
44.33B
3.4%0.6%7.8% 
20.07B
12.1%11.0%9.1%
64.93B
2.6%5.9%5.0%
33.54B
2.4%2.2%1.5%
447.57B
6.4%9.2%9.2%
29.44B
2.8%1.5%-0.3%
10.06B
12.2%12.0%14.0%
44.56B
1.3%2.6%9.3%
25.12B
7.0%8.0%8.3%
Abbott Laboratories

Abbott Laboratories Fair Value Envelope

ABT · NYSE

Our analysis suggests that ABT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $87.02, this represents a potential HIDDEN relative to our calculated worth for Abbott Laboratories.

Intrinsic Value
Current Price: $87.02